Hyrimoz®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
papulosquamous diseases
Juvenile rheumatoid arthritis
DATE:
16/08/2018
STATUS:
Authorized